Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 283

Sort by

Sort Order Select

Journal Articles

Reappearance of CXCR4 dim /CD5 bright Proliferative Fraction Associates with BTK Mutations and Anticipates Progression in Ibrutinib-Treated CLL

Blood (2023) 142 (Supplement 1): 4627.

https://doi.org/10.1182/blood-2023-174906

Published: 2023

Journal Articles

Lipid Handling Induces Ferroptosis and Conveys Sensitivity to Anti-BCMA Immunotherapy in Multiple Myeloma

Enrico La Spina, Salvatore Cortellino, Cesarina Giallongo, Marisabel Mecca, Simona Picerno, Angela Amoresano, Gabriella Pinto, Stefania Serpico, Alessandro Sgambato, Grazia Scandura, Daniela Cambria, Daniele Tibullo, Antonino Neri, Francesco Di Raimondo, Alessandra Romano

Blood (2023) 142 (Supplement 1): 4682.

https://doi.org/10.1182/blood-2023-186845

Published: 2023

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice

Blood (2023) 142 (Supplement 1): 2475.

https://doi.org/10.1182/blood-2023-179747

Published: 2023

Journal Articles

ROS-Driven Structural and Functional Fibrinogen Modifications Are Reverted By JAK Inhibition in Myeloproliferative Neoplasms

Daniele Tibullo, Giuseppe Alberto Palumbo, Cesarina Giallongo, Anna Longo, Andrea Duminuco, Francesco Di Raimondo, Enrico La Spina, Giovanni Li Volti, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Claudia Fiorillo, Niccolò Taddei, Matteo Becatti

Blood (2023) 142 (Supplement 1): 6334.

https://doi.org/10.1182/blood-2023-190029

Published: 2023

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Blood (2023) 142 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2023-181235

Published: 2023

Journal Articles

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Blood (2023) 142 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2023-177884

Published: 2023

Journal Articles

Lactate Transporters Modulate Stromal Cell Remodeling in Myeloproliferative Neoplasms (MPN)

Daniele Tibullo, Mariarita Spampinato, Andrea Duminuco, Enrico La Spina, Sebastiano Giallongo, Alessandra Romano, Grazia Scandura, Tatiana Zuppelli, Rosario Caltabiano, Lucia Salvatorelli, Giovanni Li Volti, Francesco Di Raimondo, Cesarina Giallongo, Giuseppe Alberto Palumbo

Blood (2023) 142 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2023-187452

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study

Uros Markovic, Andrea Duminuco, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro, Marina Parisi, Cinzia Maugeri, Giuseppe Milone, Alessandra Romano, Francesco Di Raimondo, Salvatore Leotta

Blood (2022) 140 (Supplement 1): 11847–11848.

https://doi.org/10.1182/blood-2022-170177

Published: 2022

Journal Articles

Arginine Deprivation in Microenvironment Makes Multiple Myeloma Resistant to Proteasome Inhibitors Via Increased Lactate Release and Metabolic Rewiring

Cesarina Giallongo, Grazia Scandura, Alessandro Barbato, Enrico La Spina, Lucia Longhitano, Tatiana Zuppelli, Ilaria Dulcamare, Nunziatina Laura Parrinello, Sebastiano Giallongo, Francesca Polito, Rosaria Oteri, Mohammed Aguennouz, Giuseppe A. Palumbo, Marco Lolicato, Giovanni Li Volti, Francesco Di Raimondo, Daniele Tibullo, Alessandra Romano

Blood (2022) 140 (Supplement 1): 7102–7103.

https://doi.org/10.1182/blood-2022-170276

Published: 2022

Journal Articles

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Elisa Gelli, Antonella Laudisi, Claudia Martinuzzi, Debora Soncini, Pamela Becherini, Fabio Guolo, Concetta Conticello, Daniele Derudas, Francesco Di Raimondo, Antonia Cagnetta, Domenico Coviello, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 7064–7065.

https://doi.org/10.1182/blood-2022-169263

Published: 2022

Journal Articles

The CXCR4 dim /CD5 bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

Federico Pozzo, Gabriela Forestieri, Giulia Ianna, Filippo Vit, Erika Tissino, Tamara Bittolo, Lodovico Terzi Di Bergamo, Roberta Laureana, Agostino Tafuri, Annalisa Chiarenza, Francesco Di Raimondo, Jacopo Olivieri, Francesco Zaja, Luca Laurenti, Maria Ilaria Del Principe, Riccardo Bomben, Antonella Zucchetto, Davide Rossi, Valter Gattei

Blood (2022) 140 (Supplement 1): 4103–4104.

https://doi.org/10.1182/blood-2022-159947

Published: 2022

Journal Articles

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Blood (2021) 138 (25): 2696–2701.

https://doi.org/10.1182/blood.2021012732

Published: 2021

Includes: Supplemental data

Journal Articles

Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma

Fabrizio Puglisi, Antonella Padella, Nunziatina Laura Parrinello, Grazia Scandura, Daniela Cambria, Enrico La Spina, Alessandro Barbato, Cesarina Giallongo, Daniele Tibullo, Giuseppe A. Palumbo, Claudio Cerchione, Giovanni Martinelli, Giorgia Simonetti, Francesco Di Raimondo, Alessandra Romano

Blood (2021) 138 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2021-151006

Published: 2021

Journal Articles

Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience

Gaetano Giuffrida, Daniela Nicolosi, Annalisa Condorelli, Uros Markovic, Francesco Di Raimondo

Blood (2021) 138 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2021-152936

Published: 2021

Journal Articles

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2021-149157

Published: 2021

NARROW

Reappearance of CXCR4 dim /CD5 bright Proliferative Fraction Associates with BTK Mutations and Anticipates Progression in Ibrutinib-Treated CLL

Lipid Handling Induces Ferroptosis and Conveys Sensitivity to Anti-BCMA Immunotherapy in Multiple Myeloma

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice

ROS-Driven Structural and Functional Fibrinogen Modifications Are Reverted By JAK Inhibition in Myeloproliferative Neoplasms

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Lactate Transporters Modulate Stromal Cell Remodeling in Myeloproliferative Neoplasms (MPN)

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study

Arginine Deprivation in Microenvironment Makes Multiple Myeloma Resistant to Proteasome Inhibitors Via Increased Lactate Release and Metabolic Rewiring

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

The CXCR4 dim /CD5 bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma

Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only